<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="774">
  <stage>Registered</stage>
  <submitdate>20/09/2005</submitdate>
  <approvaldate>26/10/2005</approvaldate>
  <actrnumber>ACTRN12605000691640</actrnumber>
  <trial_identification>
    <studytitle>The Role of Cognitive Behaviour Therapy in Cessation of Long Term Benzodiazepine Use and Outcome at 6 months</studytitle>
    <scientifictitle>The Role of Cognitive Behaviour Therapy in Cessation of Long Term Benzodiazepine Use and Outcome at 6 months</scientifictitle>
    <utrn />
    <trialacronym>Benzo withdrawal program</trialacronym>
  </trial_identification>
  <conditions>
    <healthcondition>Long term benzodiazepine use</healthcondition>
    <conditioncode>
      <conditioncode1>Other</conditioncode1>
      <conditioncode2 />
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Group 1 - Benzodiazepine dose reduction program initiated by General Practitioner plus immediate delivery of correspondence psychological skills program. Dose reduction is patient controlled and may take upto six months to cease use.

Group 2 - Benzodiazepine dose reduction program initiated by General Practitioner plus 3 mths delayed delivery of correspondence psychological skills program. Dose reduction is patient controlled and may take upto six months to cease use.</interventions>
    <comparator />
    <control>Active</control>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Cessation of benzodiazepine use</outcome>
      <timepoint>Assessed from continuous weekly self monitoring reports, and confirmed with the GP at interviews held at post-cessation.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>50% reduction of benzodiazepinedaily dose at follow-up.</outcome>
      <timepoint>At six months.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>a) have been receiving a daily dose of a benzodiazepine for a minimum continuous period of 3 months; and b) are on a stable maintenance dose of a benzodiazepine at the time of entry into the study (5-40 mg/day of diazepam or its equivalent).</inclusivecriteria>
    <inclusiveminage>0</inclusiveminage>
    <inclusiveminagetype>Not stated</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>a)  have a current diagnosis of a psychotic disorder;b)  are diagnosed with a gross brain disorder;c)  have concurrent alcohol or other non-benzodiazepine drug dependence; d)  are in current receipt of any other psychological treatment; or e)  are pregnant or nursing.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence>Generated by computer software into 20 sequences of blocks.</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>1/07/2004</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>100</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Government body</primarysponsortype>
    <primarysponsorname>Queensland Health</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>Queensland Health</fundingname>
      <fundingaddress />
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>University</sponsortype>
      <sponsorname>University of Queensland</sponsorname>
      <sponsoraddress />
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Royal Australian College of General Practice</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Cairns Base Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>University of Queensland</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Princes Alexandra Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Prince Charles Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Jan Parr</name>
      <address>Alcohol, Tobacco and Other Drugs Service
Queensland Health
PO Box 1336
Cairns QLD 4870</address>
      <phone>+61 7 40503900</phone>
      <fax>+61 7 40514151</fax>
      <email>Jan_Parr@health.qld.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Jan Parr</name>
      <address>Alcohol, Tobacco and Other Drugs Service
Queensland Health
PO Box 1336
Cairns QLD 4870</address>
      <phone>+61 7 40503900</phone>
      <fax>+61 7 40514151</fax>
      <email>Jan_Parr@health.qld.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>